Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 million
HRTX•Credit facility amended and principal reduction scheduled
Heron Therapeutics amended its credit facility with Hercules Capital, resetting financial covenants through 2027.
Outstanding principal will be cut by up to $17.5 million, including $13.5 million at execution.
A further $4 million reduction is scheduled on or before Sept. 15, 2026.
